



US008288525B2

(12) **United States Patent**
de Fougerolles et al.

(10) **Patent No.:** US 8,288,525 B2
(45) **Date of Patent:** Oct. 16, 2012

(54) **COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD45 GENE**

(75) Inventors: **Antonin de Fougerolles**, Brookline, MA (US); **Pamela Tan**, Kulmbach (DE); **Anna Borodovsky**, Cambridge, MA (US); **Tatiana Novobrantseva**, Wellesley, MA (US); **Sina Bavari**, Frederick, MD (US); **Kelly Lyn Warfield**, Adamstown, MD (US)

(73) Assignee: **Alnylam Pharmaceuticals, Inc.**, Cambridge, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **12/867,230**

(22) PCT Filed: **Feb. 12, 2009**

(86) PCT No.: **PCT/US2009/033931**

§ 371 (c)(1),
(2), (4) Date: **Oct. 27, 2010**

(87) PCT Pub. No.: **WO2009/137128**

PCT Pub. Date: **Nov. 12, 2009**

(65) **Prior Publication Data**

US 2011/0034537 A1 Feb. 10, 2011

Related U.S. Application Data

(60) Provisional application No. 61/028,162, filed on Feb. 12, 2008.

(51) **Int. Cl.**

C12Q 1/68 (2006.01)

(52) **U.S. Cl.** **536/24.5; 536/24.1; 536/24.31;**
514/44; 435/6; 435/325; 435/375

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

7,427,605	B2	9/2008	Davis et al.
7,718,629	B2	5/2010	Bumcrot et al.
2003/0143732	A1	7/2003	Fosnaugh et al.
2003/0148519	A1 *	8/2003	Engelke et al. 435/455
2003/0170891	A1	9/2003	McSwiggen
2004/0259247	A1	12/2004	Tuschl et al.
2006/0263435	A1	11/2006	Davis et al.
2007/0004664	A1	1/2007	McSwiggen et al.
2007/0031844	A1	2/2007	Khvorova et al.
2007/0281899	A1	12/2007	Bumcrot et al.
2009/0149403	A1	6/2009	MacLachlan
2009/0247614	A1 *	10/2009	Manoharan et al. 514/44 R
2011/0015250	A1	1/2011	Bumcrot et al.

FOREIGN PATENT DOCUMENTS

WO	WO 2004/080406	9/2004
WO	WO 2004/090108	10/2004

OTHER PUBLICATIONS

- Agrawal, S., et al., "Antisense oligonucleotides: towards clinical trials." *Trends in Biotechnology*. Oct. 1996, vol. 14, pp. 376-387.
 Bass, B., "The short answer," *Nature*, May 24, 2001, pp. 428-429, vol. 411.
 Elbashir, S., et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," *Methods*, 2002, pp. 199-213, vol. 26.
 Elbashir, S., et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in mammalian cell culture," *Nature*, May 24, 2001, p. 494-498, vol. 411.
 Elbashir, S., et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in Drosophila Melanogaster Embryo Lysate", *The EMBO Journal*, 2001, pp. 6877-6888, vol. 20, No. 23.
 Elbashir, S., et al., "RNA Interference is Mediated by 21-and 22 Nucleotide RNAs," *Genes & Development*, 2001, pp. 188-200, vol. 15.
 Fire, A., "RNA-triggered Gene Silencing," *Trends in Genetics*, Sep. 1999, pp. 358-363, vol. 15, No. 9.
 Fire, A., et al., "Potent and Specific Genetic Interference by Double Stranded RNA in *Caenorhabditis elegans*," *Nature*, Feb. 19, 1998, pp. 806-811, vol. 391.
 Tuschl, T., "Functional genomics: RNA sets the standard," *Nature*, Jan. 16, 2003, vol. 421, No. 6920, pp. 220-221.
 Tuschl, T., "RNA Interference and Small Interfering RNAs" *Chembiochem*, 2001, pp. 239-245, vol. 2.
 Tuschl, T., et al., "Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy," *Molecular Interventions*, 2002, pp. 158-167, vol. 2, No. 3.
 Tuschl, T., "Mammalian RNA Interference," *RNAi, A Guide to Gene Silencing*, Chapter 13, G.J. Hannon (ed.), 2003, pp. 265-295.
 Tuschl, T., et al., "Targeted mRNA Degradation by Double-Stranded RNA in Vitro," *Genes & Development*, 1999, pp. 3191-3197, vol. 13.
 Tuschl, T., "Expanding small RNA interference," *Nature Biotechnology*, May 2002, pp. 446-448, vol. 20.
 Vickers, T., et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents," *The Journal of Biological Chemistry*, Feb. 28, 2003, pp. 7108-7118, vol. 278, No. 9.
 Maurer, N., et al. "Spontaneous Entrapment of Polynucleotides Upon Electrostatic Interaction with Ethanol-Destabilized Cationic Liposomes," *Biophysical Journal*, May 2001, pp. 2310-2326, vol. 80.
 Semple, S., et al., "Efficient Encapsulation of Antisense Oligonucleotides in Lipid Vesicles Using Ionizable Aminolipids: Formation of Novel Small Multilamellar Vesicle Structures," *Biochim. Biophys. Acta*, 2001, pp. 152-166, vol. 1510.
 Anand, A.R., et al., "HIV-1, gp120-mediated apoptosis of T cells is regulated by the membrane tyrosine phosphatase CD45," *Journal of Biological Chemistry*, May 2006, pp. 12289-12299, vol. 281, No. 18.
 Hermiston, M., et al., "CD45: a critical regulator of signaling thresholds in immune cells," *Annual review of immunology*, 2003, vol. 21, pp. 107-137.
 Oliveira, D.M., et al., "Transient RNA interference in hematopoietic progenitors with functional consequences," *Genesis*, Aug. 2003, pp. 203-208, vol. 36, No. 4.
 Tchilian, E., et al., "Altered CD45 expression and disease," *Trends in Immunology*, Mar. 2006, pp. 146-153, vol. 27, No. 3.

(Continued)

Primary Examiner — Kimberly Chong

(74) Attorney, Agent, or Firm — Fenwick & West LLP

(57) **ABSTRACT**

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the CD45 gene.